Literature DB >> 19359974

An evaluation of the impact of apheresis platelets used in the setting of massively transfused trauma patients.

Jeremy G Perkins1, Andrew P Cap, Cap P Andrew, Philip C Spinella, Lorne H Blackbourne, Kurt W Grathwohl, Thomas B Repine, Lloyd Ketchum, Paige Waterman, Ruth E Lee, Alec C Beekley, James A Sebesta, Andrew F Shorr, Charles E Wade, John B Holcomb.   

Abstract

INTRODUCTION: Trauma is a major cause of morbidity and mortality worldwide. Of patients arriving to trauma centers, patients requiring massive transfusion (MT, >or=10 units in 24 hours) are a small patient subset but are at the highest risk of mortality. Transfusion of appropriate ratios of blood products to such patients has recently been an area of interest to both the civilian and military medical community. Plasma is increasingly recognized as a critical component, though less is known about appropriate ratios of platelets. Combat casualties managed at the busiest combat hospital in Iraq provided an opportunity to examine this question.
METHODS: In-patient records for 8,618 trauma casualties treated at the military hospital in Baghdad more than a 3-year interval between January 2004 and December 2006 were retrospectively reviewed and patients requiring MT (n = 694) were identified. Patients who required MT in the first 24 hours and did not receive fresh whole blood were divided into study groups defined by source of platelets: (1) patient receiving a low ratio of platelets (<1:16 apheresis platelets per stored red cell unit, aPLT:RBC) (n = 214), (2) patients receiving a medium ratio of platelets (1:16 to <1:8 aPLT:RBC) (n = 154), and (3) patients receiving a high ratio of platelets (>or=1:8 aPLT:RBC) (n = 96). The primary endpoint was survival at 24 hours and at 30 days.
RESULTS: At 24 hours, patients receiving a high ratio of platelets had higher survival (95%) as compared with patients receiving a medium ratio (87%) and patients receiving the lowest ratio of platelets (64%) (log-rank p = 0.04 and p < 0.001, respectively). The survival benefit for the high and medium ratio groups remained at 30 days as compared with those receiving the lowest ratio of platelets (75% and 60% vs. 43%, p < 0.001 for both comparisons). On multivariate regression, plasma:RBC ratios and aPLT:RBC were both independently associated with improved survival at 24 hours and at 30 days.
CONCLUSION: Transfusion of a ratio of >or=1:8 aPLT:RBC is associated with improved survival at 24 hours and at 30 days in combat casualties requiring a MT within 24 hours of injury. Although prospective study is needed to confirm this finding, MT protocols outside of investigational research should consider incorporation of appropriate ratios of both plasma and platelets.

Entities:  

Mesh:

Year:  2009        PMID: 19359974     DOI: 10.1097/TA.0b013e31819d8936

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  29 in total

1.  A multidisciplinary "think tank": the top 10 clinical trial opportunities in transfusion medicine from the National Heart, Lung, and Blood Institute-sponsored 2009 state-of-the-science symposium.

Authors:  Cassandra D Josephson; Simone A Glynn; Steve H Kleinman; Morris A Blajchman
Journal:  Transfusion       Date:  2010-10-04       Impact factor: 3.157

Review 2.  Coagulation abnormalities in the trauma patient: the role of point-of-care thromboelastography.

Authors:  Eduardo Gonzalez; Fredric M Pieracci; Ernest E Moore; Jeffry L Kashuk
Journal:  Semin Thromb Hemost       Date:  2010-10-26       Impact factor: 4.180

3.  Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial.

Authors:  John B Holcomb; Barbara C Tilley; Sarah Baraniuk; Erin E Fox; Charles E Wade; Jeanette M Podbielski; Deborah J del Junco; Karen J Brasel; Eileen M Bulger; Rachael A Callcut; Mitchell Jay Cohen; Bryan A Cotton; Timothy C Fabian; Kenji Inaba; Jeffrey D Kerby; Peter Muskat; Terence O'Keeffe; Sandro Rizoli; Bryce R H Robinson; Thomas M Scalea; Martin A Schreiber; Deborah M Stein; Jordan A Weinberg; Jeannie L Callum; John R Hess; Nena Matijevic; Christopher N Miller; Jean-Francois Pittet; David B Hoyt; Gail D Pearson; Brian Leroux; Gerald van Belle
Journal:  JAMA       Date:  2015-02-03       Impact factor: 56.272

4.  Utility and development of microfluidic platforms for platelet research.

Authors:  Jevgenia Zilberman-Rudenko; Owen J T McCarty
Journal:  Platelets       Date:  2017-07       Impact factor: 3.862

Review 5.  Coagulopathy after severe pediatric trauma.

Authors:  Sarah C Christiaans; Amy L Duhachek-Stapelman; Robert T Russell; Steven J Lisco; Jeffrey D Kerby; Jean-François Pittet
Journal:  Shock       Date:  2014-06       Impact factor: 3.454

Review 6.  Optimal use of blood products in severely injured trauma patients.

Authors:  John B Holcomb
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

7.  Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementation.

Authors:  Sarah Baraniuk; Barbara C Tilley; Deborah J del Junco; Erin E Fox; Gerald van Belle; Charles E Wade; Jeanette M Podbielski; Angela M Beeler; John R Hess; Eileen M Bulger; Martin A Schreiber; Kenji Inaba; Timothy C Fabian; Jeffrey D Kerby; Mitchell Jay Cohen; Christopher N Miller; Sandro Rizoli; Thomas M Scalea; Terence O'Keeffe; Karen J Brasel; Bryan A Cotton; Peter Muskat; John B Holcomb
Journal:  Injury       Date:  2014-06-10       Impact factor: 2.586

Review 8.  The Evolution of Damage Control in Concept and Practice.

Authors:  Brian C Beldowicz
Journal:  Clin Colon Rectal Surg       Date:  2017-12-19

Review 9.  Resuscitation and transfusion principles for traumatic hemorrhagic shock.

Authors:  Philip C Spinella; John B Holcomb
Journal:  Blood Rev       Date:  2009-08-19       Impact factor: 8.250

Review 10.  Management of bleeding and coagulopathy following major trauma: an updated European guideline.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2013-04-19       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.